Results 121 to 130 of about 70,369 (254)

Mammalian target of rapamycin inhibition protects glioma cells from temozolomide-induced cell death

Cell Death Discovery
Glioblastoma is an incurable brain tumor with a median survival below two years. Trials investigating targeted therapy with inhibitors of the kinase mTOR have produced ambiguous results.
Benedikt Sauer, Nadja I. Lorenz, Iris Divé, Kevin Klann, Anna-Luisa Luger, Hans Urban, Jan-Hendrik Schröder, Joachim P. Steinbach, Christian Münch, Michael W. Ronellenfitsch   +9 more
doaj   +1 more source

Pegargiminase Suppresses the Fanconi Anemia Pathway and Promotes Melphalan‐Induced DNA Double‐Strand Breaks in Uveal Melanoma

Pigment Cell &Melanoma Research, Volume 39, Issue 4, July 2026.
ADI‐PEG20 enhances melphalan‐induced DNA DSBs in UM cells. We describe potentiation of DNA DSBs in UM cell lines upon treatment with ADI‐PEG20 and melphalan (92.1 cells with STRIDE by intoDNA). ADI‐PEG20 suppresses multiple members of the FA pathway—a known resistance mechanism for melphalan—providing a rationale for exploring this drug combination in ...
Iuliia Pavlyk, George Field, Matthew Young, Josephine Carpentier, Emilia A. Szlosarek, Michaela R. O'Keeffe‐Brown, Timothy Crook, Nelofer Syed, John S. Bomalaski, Pui Ying Chan, Peter W. Szlosarek   +10 more
wiley   +1 more source

List of temozolomide (TMZ)-mediated microRNAs.

, 2016
List of temozolomide (TMZ)-mediated microRNAs.
Cheng-Wei Lin (1668613), Cheng-Kuei Chang (3366413), Kuo-Hao Ho (3366419), Chwen-Ming Shih (156200), Peng-Hsu Chen (3366416), Ku-Chung Chen (334175), Ann-Jeng Liu (3168012), Chia-Hsiung Cheng (211531), Chin-Cheng Lee (156187)   +8 more
core   +1 more source

Chlorpromazine overcomes temozolomide resistance in glioblastoma by inhibiting Cx43 and essential DNA repair pathways

Journal of Translational Medicine
Background In the fight against GBM, drug repurposing emerges as a viable and time-saving approach to explore new treatment options. Chlorpromazine, an old antipsychotic medication, has recently arisen as a promising candidate for repositioning in GBM ...
Paola Matarrese, Michele Signore, Barbara Ascione, Giulia Fanelli, Marco G. Paggi, Claudia Abbruzzese   +5 more
doaj   +1 more source

Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas

International Journal of Cancer, Volume 158, Issue 12, Page 3217-3231, 15 June 2026.
What's new? Colorectal neuroendocrine carcinoma (CR‐NEC) is a rare digestive neuroendocrine neoplasm that frequently exhibits an adenocarcinoma component. Nonetheless, the underlying biology of CR‐NEC remains poorly understood. This study examined molecular and clinical features and palliative chemotherapy outcomes of metastatic CR‐NEC, with comparison
Siren Morken, Seppo W. Langer, Geir Olav Hjortland, Anna Sundlöv, Eva Hofsli, Morten Ladekarl, Elizaveta Tabaksblat, Lene Weber Vestermark, Johanna Svensson, Ulrich Knigge, Luís Nunes, Bengt Glimelius, Per Pfeiffer, Kristine Aasebø, Jörg Assmus, Erik Vassella, Inger Marie Bowitz Lothe, Anne Couvelard, Aurel Perren, Stian Knappskog, Halfdan Sorbye   +20 more
wiley   +1 more source

Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy

, 2006
Purpose: To compare the ability of positron emission tomography (PET) to predict response to temozolomide vs. temozolomide plus radiotherapy. Methods and Materials: Nineteen patients with high-grade glioma (HGG) were studied.
Price, Pat, Barnett, Carolyn M., Matthews, Julian; id_orcid, Newlands, Ed S., Bydder, Graeme M., West, Catharine M.; id_orcid, Brock, Catherine, Swindell, Ric, Glaser, Mark, Charnley, Natalie   +9 more
core   +1 more source

Application progress of temozolomide in clinical tumor chemotherapy

Chinese Journal of Contemporary Neurology and Neurosurgery, 2013
Temozolomide is an imidazotetrazine derivative of the alkylating agent, which is used to treat central nervous system tumors, especially malignant brain gliomas. It is a milestone in brain giloma chemotherapy. Recently, some researchers used temozolomide
Cheng ZHONG, Bin WANG, Sheng-qing LV
doaj  

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, Volume 20, Issue 6, Page 1398-1419, June 2026.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

The effect of temozolomide as consolidation chemotherapy on treatment results of glioblastoma multiforme patients treated with concomittant radiotherapy and temozolomide

, 2008
This retrospective study was performed to determine the efficacy of adjuvant temozolomide after radiotherapy with concomitant temozolomide in patients with newly diagnosed glioblastome ...
Soyuer, Serdar, Kaplan, Buenyamin, EROĞLU, Celalettin, ÖZKAN, Metin, YILDIZ, Oguz G., Menku, Ahmet, Orhan, Okan   +6 more
core  

NKCC1: A key regulator of glioblastoma progression

Molecular Oncology, Volume 20, Issue 6, Page 1420-1428, June 2026.
Glioblastoma (GBM) progression is driven by disrupted chloride cotransporter homeostasis. NKCC1 is highly expressed in stem‐like, astrocytic, and progenitor cells, correlating with earlier recurrence, while overall survival remains unaffected. NKCC1 serves as a prognostic marker and potential therapeutic target, linking chloride transporter imbalance ...
Anja Thomsen, Diana Freitag, Madlen Haase, Christian Senft, Falko Schwarz, Silke Keiner   +5 more
wiley   +1 more source